Juvenile myoclonic epilepsy

Juvenile myoclonic epilepsy (JME), also known as Janz syndrome or impulsive petit mal epilepsy, is one of the most common forms of genetic generalized epilepsy. It typically begins during adolescence, usually between the ages of 12 and 18 years, and affects the central nervous system. JME is characterized by a triad of seizure types: myoclonic jerks (sudden, brief involuntary muscle contractions), generalized tonic-clonic seizures (convulsions), and, in approximately one-third of patients, absence seizures (brief episodes of staring and unresponsiveness). The myoclonic jerks most commonly occur shortly after awakening and predominantly affect the shoulders and arms, often causing patients to drop objects. Seizures are frequently triggered by sleep deprivation, fatigue, stress, and alcohol consumption. JME has a strong genetic basis, with multiple susceptibility loci identified, including genes such as EFHC1, GABRA1, and CLCN2, among others. The condition follows a complex (multifactorial) inheritance pattern, though some families show autosomal dominant transmission with variable penetrance. A family history of epilepsy is present in a significant proportion of affected individuals. Electroencephalography (EEG) typically shows generalized 4–6 Hz polyspike-and-wave discharges, which are a hallmark diagnostic feature. Treatment of JME relies primarily on antiseizure medications, with valproic acid (valproate) being considered the most effective first-line therapy, particularly in males. Levetiracetam and lamotrigine are commonly used alternatives, especially in women of childbearing age due to the teratogenic risks of valproate. Most patients achieve good seizure control with appropriate medication; however, JME is generally considered a lifelong condition, and seizure recurrence rates are high upon medication withdrawal. Lifestyle modifications, including maintaining regular sleep patterns and avoiding known seizure triggers, are an important component of management.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Juvenile myoclonic epilepsy